Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Are the Current Preclinical Models Adequate to Evaluate CAR-T Cell Therapy in Paediatric High-Grade Gliomas?

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Dual tumour-myeloid targeting of glioblastoma with GPNMB CAR-T cells.

Nature·2026
Same author

Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

TP63 expression correlates with mesenchymal-like gene signature in patient-derived recurrent glioblastoma cells.

Biochemical and biophysical research communications·2026
Same author

uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target.

Science translational medicine·2026
Same author

Generation of Allogeneic CAR-T Circumvents Functional Deficits in Patient-Derived Autologous Product for Glioblastoma.

International journal of cancer·2026

相关实验视频

Updated: Sep 20, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K

针对性的放射性核素治疗使用标记为卢塞-177的人类抗CD133抗体的抗体.

Kevin Wyszatko1, Nancy Janzen1, Napoleon Law2

  • 1Department of Chemistry and Chemical Biology, McMaster University, Hamilton, ON, Canada.

Molecular imaging and biology
|May 22, 2025
PubMed
概括
此摘要是机器生成的。

使用标记为luteetium-177的抗CD133抗体 ([177Lu]Lu-DOTA-RW03) 的向放射性核酸治疗显示出治疗耐火性癌症的希望. 这种疗法有效地向癌症干细胞,减少瘤生长,并在临床前模型中增加存活率.

关键词:
CD133 是一个CD133 CD133 是一个CD133癌症干细胞是癌症的干细胞.放射性免疫疗法是一种放射性免疫疗法.有针对性的放射性核酸治疗.

更多相关视频

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.0K

相关实验视频

Last Updated: Sep 20, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.2K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.9K
Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
11:34

Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT

Published on: April 29, 2017

9.0K

科学领域:

  • 核医学是一种核医学.
  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.

背景情况:

  • 癌症干细胞 (CSCs) 与瘤复发和治疗耐药性有关.
  • 针对像CD133这样的CSC特异性标记物提供了一种消除这些弹性细胞的策略.
  • 耐火性瘤通常含有大量的CSC群体,需要新的治疗方法.

研究的目的:

  • 合成和评估[177Lu]Lu-DOTA-RW03,一种针对CD133进行癌症治疗的新型放射性免疫结合物.
  • 评估[177Lu]Lu-DOTA-RW03在表达CD133的结直肠癌模型中的体外结合特性,体内生物分布和疗效.

主要方法:

  • 完全人类抗CD133抗体 (RW03) 与DOTA-NHS的结合,随后用-177.7进行放射性标记.
  • 在体外结合测定使用CD133表达HT-29细胞来确定亲和力和免疫活性.
  • 在免疫缺陷小鼠携带HT-29异种移植的体内生物分布,SPECT成像和剂量升级治疗研究.

主要成果:

  • [177Lu]Lu-DOTA-RW03成功合成了高放射化学纯度和产量,表现出极好的结合亲和力和免疫活性.
  • 在体内观察到显著的瘤吸收和有利的瘤对血液比率,证实了抗原特异性.
  • 证明了剂量依赖的治疗疗效,包括减少瘤生长和增加存活率,以及瘤死的证据.

结论:

  • [177Lu]Lu-DOTA-RW03显示出作为一种有效的向放射性核素治疗CD133表达癌症的显著潜力.
  • 这些发现支持进一步调查[177Lu]Lu-DOTA-RW03用于耐火性瘤的多剂量和组合治疗策略.